Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.

ABSTRACT: Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p?=?.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p?=?.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.

SUBMITTER: Merryman RW 

PROVIDER: S-EPMC7288660 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature